IL-33 levels in Egyptian psoriasis patients
Part of Immune system & allergy, Skin clinical trials.
This study looks at a marker called IL-33 in the blood of people with moderate to severe psoriasis. It aims to see if IL-33 levels are different in psoriasis and might help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have moderate to severe psoriasis, meaning it covers more than 5% of your body.
- You are not pregnant or breastfeeding.
- You do not have other inflammatory, autoimmune, or major health conditions like high blood pressure, kidney disease, or liver disease.
- You have not used systemic treatments, phototherapy, or have an allergy to methotrexate or cyclosporine in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a protein in the blood called interleukin-33 is linked to lupus symptoms)Skip
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study looks at the immune cells in skin samples from people with psoriasis who are being treated with an anti-IL-23 biologic. The goal is to understand why some areas of skin do not improve or why flares happen, which may help improve treatments.
This study looks at a specific gene (Card14) in Egyptian patients with psoriasis or psoriatic arthritis. It may help understand why some people get these conditions and how they could be treated better.
This study looks at the level of a protein called IL-41 in the blood of people with ankylosing spondylitis or psoriatic arthritis, compared to healthy people. The goal is to see if this protein could be used as a marker to help understand or diagnose these conditions.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hear when a new Egyptian Psoriatic Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.